Sg3 Management, LLC Arrowhead Pharmaceuticals, Inc. Call Options Transaction History

Sg3 Management, LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 14, 2023	BUY	$28.0 - $40.56 $378,000 - $547,560	13,500 New	13,500 $547,000
Q1 2022 May 16, 2022	SELL	$39.62 - $69.97 $396,200 - $699,700	-10,000 Closed	0 $0
Q4 2021 Feb 15, 2022	SELL	$58.09 - $82.51 $1.16 Million - $1.65 Million	-20,000 Reduced 66.67%	10,000 $663,000
Q3 2021 Nov 15, 2021	BUY	$58.38 - $84.96 $1.56 Million - $2.27 Million	26,700 Added 809.09%	30,000 $1.87 Million
Q2 2021 Aug 16, 2021	SELL	$62.15 - $90.32 $3.42 Million - $4.97 Million	-55,000 Reduced 94.34%	3,300 $273,000
Q1 2021 May 17, 2021	BUY	$61.35 - $90.47 $2.96 Million - $4.37 Million	48,300 Added 483.0%	58,300 $3.87 Million
Q3 2020 Nov 13, 2020	BUY	$33.21 - $51.27 $332,100 - $512,700	10,000 New	10,000 $431,000

294

90.8M

155K

426K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.08B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.